Alnylam Pharmaceuticals, Inc (ALNY)

80.51
4.38 5.16
NASDAQ
Prev Close 84.89
Open 85.06
Day Low/High 79.79 / 86.23
52 Wk Low/High 60.27 / 153.99
Volume 849.23K
Exchange NASDAQ
Shares Outstanding 106.44B
Market Cap 9.43B
Div & Yield N.A. (N.A)

Latest News

Alnylam And Regeneron Announce Broad Collaboration To Discover, Develop And Commercialize RNAi Therapeutics Focused On Ocular And Central Nervous System (CNS) Diseases

Alnylam And Regeneron Announce Broad Collaboration To Discover, Develop And Commercialize RNAi Therapeutics Focused On Ocular And Central Nervous System (CNS) Diseases

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Regeneron Pharmaceuticals, Inc.

Alnylam And Sanofi Conclude Research And Option Phase Of 2014 RNAi Therapeutics Collaboration

Alnylam And Sanofi Conclude Research And Option Phase Of 2014 RNAi Therapeutics Collaboration

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that Alnylam and Sanofi have agreed to conclude the research and option phase of the companies' 2014 RNAi therapeutics alliance in rare genetic diseases.

Lack of Euphoria: Cramer's 'Mad Money' Recap (Tuesday 4/2/19)

Lack of Euphoria: Cramer's 'Mad Money' Recap (Tuesday 4/2/19)

The decided lack of enthusiasm for Lyft is really good for this market, says Jim Cramer. It shows investors are behaving rationally.

Mastercard, Carrizo Oil & Gas, Duluth Holdings: 'Mad Money' Lightning Round

Mastercard, Carrizo Oil & Gas, Duluth Holdings: 'Mad Money' Lightning Round

Jim Cramer weighs in on Mastercard, Carrizo Oil & Gas, Duluth Holdings, Alnylam Pharmaceuticals, United States Steel.

Alnylam To Present Givosiran Phase 3 Data At The European Association For The Study Of The Liver (EASL) International Liver Congress™

Alnylam To Present Givosiran Phase 3 Data At The European Association For The Study Of The Liver (EASL) International Liver Congress™

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company and its collaborators will present at the European Association for the Study of the Liver (EASL) 54 th Annual International Liver...

Alnylam Submits CTA Application For ALN-AGT, An Investigational RNAi Therapeutic For The Treatment Of Hypertension In High Unmet Need Settings

Alnylam Submits CTA Application For ALN-AGT, An Investigational RNAi Therapeutic For The Treatment Of Hypertension In High Unmet Need Settings

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Healthcare products Regulatory Agency (MHRA) in the...

Alnylam To Webcast Presentation At Cowen & Company 39th Annual Health Care Conference

Alnylam To Webcast Presentation At Cowen & Company 39th Annual Health Care Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Cowen & Company 39 th Annual Health Care Conference on Wednesday, March 13, 2019 at 11:20 am ET at...

Alnylam Reports Positive Topline Results From ENVISION Phase 3 Study Of Givosiran In Acute Hepatic Porphyria

Alnylam Reports Positive Topline Results From ENVISION Phase 3 Study Of Givosiran In Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the...

Alnylam Announces Recipients Of First Annual Advocacy For Impact Grants Program

Alnylam Announces Recipients Of First Annual Advocacy For Impact Grants Program

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced support for seven patient advocacy groups through the Advocacy for Impact Grants program.

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

As the U.S. and the world grow fatter, some investors are seeing green as they bulk up on stocks of companies on the front-lines of this 21st century Battle of the Bulge.

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2018 and reviewed recent commercial and R&D highlights.

Alnylam Announces Publication Of Phase 1 Givosiran Data In The New England Journal Of Medicine

Alnylam Announces Publication Of Phase 1 Givosiran Data In The New England Journal Of Medicine

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that results from the Phase 1 study of givosiran, an investigational, subcutaneous RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for...

Alnylam To Webcast Presentations At Upcoming February Investor Conferences

Alnylam To Webcast Presentations At Upcoming February Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 21 st Annual BIO CEO & Investor Conference on Monday, February 11, 2019 at...

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2018 Financial Results

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2018 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2018 on Thursday, February 7, 2019, after the U.

Alnylam Pharmaceuticals Prices Public Offering Of Common Stock

Alnylam Pharmaceuticals Prices Public Offering Of Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $77.

Alnylam Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Alnylam Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock.

Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues For ONPATTRO® (patisiran) And Provides Additional Commercial Updates

Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues For ONPATTRO® (patisiran) And Provides Additional Commercial Updates

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today pre-announced its unaudited fourth quarter 2018 global net product revenues for ONPATTRO and provided additional updates on the product's commercial launch.

Alnylam To Webcast Presentation At 37th Annual J.P. Morgan Healthcare Conference

Alnylam To Webcast Presentation At 37th Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 37 th Annual J.

Alnylam Announces Settlement Of Litigation With Silence Therapeutics

Alnylam Announces Settlement Of Litigation With Silence Therapeutics

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has resolved all litigation worldwide with Silence Therapeutics.

Alnylam Provides R&D Updates And Announces 2019 Product And Pipeline Goals At R&D Day

Alnylam Provides R&D Updates And Announces 2019 Product And Pipeline Goals At R&D Day

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announces it is hosting its R&D Day in New York City today.

Alnylam To Webcast R&D Day

Alnylam To Webcast R&D Day

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the Company's website, www.

DEADLINE TODAY: The Schall Law Firm Announces It Is Investigating Claims Against Alnylam Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

DEADLINE TODAY: The Schall Law Firm Announces It Is Investigating Claims Against Alnylam Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc.

Vir Biotechnology And Alnylam Pharmaceuticals Initiate Phase 1/2 Study Of VIR-2218

Vir Biotechnology And Alnylam Pharmaceuticals Initiate Phase 1/2 Study Of VIR-2218

Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc.

DEADLINE MONDAY: The Schall Law Firm Announces It Is Investigating Claims Against Alnylam Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

DEADLINE MONDAY: The Schall Law Firm Announces It Is Investigating Claims Against Alnylam Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc.

CURRENT SHAREHOLDERS: Zamansky LLC Investigates Alnylam Pharmaceuticals (ALNY) For Potential Breaches Of Fiduciary Duties

CURRENT SHAREHOLDERS: Zamansky LLC Investigates Alnylam Pharmaceuticals (ALNY) For Potential Breaches Of Fiduciary Duties

Zamansky LLC announces that it is investigating Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NasdaqGS: ALNY) for potential breaches of fiduciary duties by its senior officers and board of directors.

Alnylam To Webcast Presentations At Upcoming Investor Conferences

Alnylam To Webcast Presentations At Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 30 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28,...

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Alnylam Pharmaceuticals, Inc.

TheStreet Quant Rating: D (Sell)